May 23, 2015
Below are current clinical trials.497 studies in Cancer
(open studies only).
Filter this list of studies by location, status and more.
La Crosse, Wis., Rochester, Minn., Mankato, Minn.
This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
The purpose of this study is to determine if Stereotactic Ablative Radiotherapy improves survival over sublobar resaction in high risk operable stage I non-small cell lung cancer.
Does Tai Chi Easy (TCEasy), a simple and repetitive form of exercise that consists of movements with meditation, improve quality of life in those afflicted with multiple myeloma undergoing autologous stem cell transplantation?
The purpose of this study is to compare conventional assessment of systolic ventricular function on a 2D heart echo with an assessment of more immediate changes in heart mechanics using 2D and 3D measurements of deformation and strain in patients undergoing infusion of Trastuzumab for breast cancer.
RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma.
This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). The planned duration of this study is approximately 36 months. Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F.
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
Information regarding the delay in diagnosis as well as the causes of the delay are lacking in the U.S. Specifically, we aim to identify patient factors and provider factors that contribute to delayed diagnosis of sarcoma.
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
- Deaths and mortality. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/deaths.htm. Accessed April 23, 2015.
- Cancer: All sites. Surveillance Epidemiology and End Results. http://seer.cancer.gov/statfacts/html/all.html. Accessed April 23, 2015.
- Symptoms. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/symptoms. Accessed April 23, 2015.
- Kushi LH, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians. 2012;62:30.
- Niederhuber JE, et al., eds. Genetic and epigenetic alterations in cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed April 23, 2015.
- Ulcerative colitis. National Institute of Diabetes and Digestive and Kidney Diseases. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.htm. Accessed April 23, 2015.
- NINDS paraneoplastic syndromes information page. National Institute of Neurological Disorder and Stroke. http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm. Accessed April 23, 2015.
- Deng GE, et al. Evidence-based clinical practice guidelines for integrative oncology: Complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009;7:85.
- Taking time: Support for people with cancer. National Cancer Institute. http://cancer.gov/cancertopics/takingtime. Accessed April 23, 2015.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. May 1, 2015.
- Hypercalcemia (high level of calcium in the blood). Merck Manual Home Edition. http://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/electrolyte-balance/hypercalcemia-high-level-of-calcium-in-the-blood. Accessed April 23, 2015.
- What is cancer? National Cancer Institute. http://www.cancer.gov/cancertopics/what-is-cancer. Accessed April 23, 2015.
- Cancer prevention overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient/page1/AllPages. Accessed April 23, 2015.
- The genetics of cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/causes-prevention/genetics. Accessed April 23, 2015.
- Understanding cancer risk. Cancer.Net. http://www.cancer.net/navigating-cancer-care/prevention-and-healthy-living/understanding-cancer-risk. Accessed April 23. 2015.
- Cancer screening overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/overview/HealthProfessional. Accessed April 23, 2015.
- Diagnosis. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/diagnosis. Accessed April 23, 2015.
- Staging. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/staging. Accessed April 23, 2015.
- Making decisions about cancer treatment. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment. Accessed April 23, 2015.
- How cancer is treated. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated. Accessed April 23, 2015.